Interview: Éric Gervais, Executive Vice President, Médunik Canada
As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country, talks about the desperate…
Médunik Canada is dedicated to developing strong partnerships with non-Canadian pharmaceutical and biopharmaceutical companies that are attempting to optimize the return on investment of their orphan drugs; they need to balance the financial risks and complexities associated to the introduction and distribution of their products on the small-size Canadian market. Through in-licensing partnerships, Médunik Canada offers turn-key operations – ranging from regulatory approval strategy to post-approval activities – to assure the commercial success of the partners’ product development efforts.
Medunik Canada
950, boul. Michèle-Bohec
Blainville (Québec) Canada
J7C 5E2
Tel.: + 1 450 433-4441
Fax: + 1 450 433-2211
As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country, talks about the desperate…
Éric Gervais, executive vice-president of Duchesnay Inc, a privately-held, specialty Canadian pharma company focusing on women’s health, charts the company’s successful growth over the past 25 years, the innovative portfolio…
Doug Sommerville, senior vice-president and general manager of Teva Canada, discusses Teva Canada’s enviable top five positioning within the global organization, the strength of Teva’s generics portfolio within Canada, and…
Ronnie Miller, President & CEO of Roche Canada, shares the lessons learnt over his 17 years heading the affiliate, the interesting dynamics and developments within the Canadian healthcare space, Roche’s…
Dr. Roman Szumski, vice-president of life sciences at the National Research Council (NRC), Canada’s industrial innovation and research organization, highlights the strategic and operational changes that have occurred over the…
Clarissa Desjardins is the founder and CEO since 2011 of Canadian biotech success story, Clementia Pharmaceuticals. She explains the different milestones of her company and her priorities moving forward. She…
With cost-cutting measures exacerbating an already fraught regulatory process, the Canadian generics industry is facing somewhat of an existential crisis. However, within this difficult market environment, enterprising generics companies are…
Chirfi Guindo, president and managing director of Merck Canada, highlights the stunning transformation that has led to a revitalized new Merck affiliate, the innovation opportunities Canada’s fragmented and diverse health…
Newly appointed minister of health of Canada, The Honourable Ginette Petitpas Taylor, shares the core tenets of her mandate, the Federal government’s priorities for investment into the Canadian healthcare ecosystem,…
Wendy Adams, general manager of Galderma Canada, outlines the main achievements of the affiliate since 2013, the best practices she can share with Galderma globally when it comes to managing…
Paul-Émile Cloutier, president & CEO of HealthCareCAN, the national voice of healthcare organizations and hospitals across Canada, highlights his ambition to make HealthCareCAN the go-to resource on healthcare system topics,…
Mark Lachovsky, founder and president of Accel Pharma, a Canadian generics company with a unique business model, discusses the inspiring story of how he started and grew the company through…
Brian Hilberdink, President of Novo Nordisk Canada, highlights the key role that Canada plays as a pilot market for exporting best practices globally, the focus that Novo Nordisk is placing…
See our Cookie Privacy Policy Here
